Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib and Sorafenib in Recurrent Glioblastoma
NCT00445588Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 2007
- Primary completion
- Aug 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of erlotinib, sorafenib in glioblastoma multiforme (GBM), sponsored by National Cancer Institute. Started Jan 2007; status: completed.
02
Drugs
erlotinibsorafenib
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT00445588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00445588.